We are testing a new drug, CP-506, in patients with specific solid tumors to see how safe it is and how well it works. This study may help those with tumors that have certain genetic features or who are not responding well to current treatments.
Health conditions and diseases that the clinical trial is designed to study and treat.
This condition refers to solid tumors that exhibit a high incidence of deficiencies in DNA damage repair mechanisms, specifically Homologous Recombination Deficiency (HRD) and Fanconi Anemia (FAD). These deficiencies can affect how tumors respond to certain treatments.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
